Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trialResearch in context
Summary: Background: Smoking cessation is challenging, despite making use of established smoking cessation therapies. Preclinical studies and one clinical pilot study suggest the antidiabetic drug glucagon-like peptide-1 (GLP-1) analogue to modulate addictive behaviours and nicotine craving. Previo...
Main Authors: | Hualin Lüthi, Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, Tanja Vukajlovic, Katja Bologna, Michelle Steinmetz, Cemile Bathelt, Clara O. Sailer, Mirjam Laager, Deborah R. Vogt, Lars G. Hemkens, Benjamin Speich, Sandrine A. Urwyler, Jill Kühne, Fabienne Baur, Linda N. Lutz, Tobias E. Erlanger, Mirjam Christ-Crain, Bettina Winzeler |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-02-01
|
Series: | EClinicalMedicine |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537024000087 |
Similar Items
-
Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trialResearch in context
by: Sophia Lengsfeld, et al.
Published: (2023-03-01) -
Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)—a structured summary of a study protocol for a randomized controlled study
by: Sophia Lengsfeld, et al.
Published: (2023-04-01) -
Effects of dulaglutide on alcohol consumption during smoking cessation
by: Leila Probst, et al.
Published: (2023-11-01) -
Gender differences in weight gain during attempted and successful smoking cessation on dulaglutide treatment: a predefined secondary analysis of a randomised trial
by: Mirjam Christ-Crain, et al.
Published: (2023-12-01) -
Predictors of past quit attempts and duration of abstinence among cigarette smokers
by: N. Layoun, et al.
Published: (2017-07-01)